State Street’s Gyre Therapeutics GYRE Stock Holding History

State Street’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.51M	Buy	216,326 +14,101	+7%	+$110K	﹤0.01%	3383
2025 Q4	$1.43M	Buy	202,225 +19,472	+11%	+$150K	﹤0.01%	3441
2025 Q3	$1.36M	Buy	182,753 +4,985	+3%	+$37.9K	﹤0.01%	3442
2025 Q2	$1.31M	Buy	177,768 +48,995	+38%	+$427K	﹤0.01%	3434
2025 Q1	$994K	Buy	128,773 +2,126	+2%	+$23.3K	﹤0.01%	3428
2024 Q4	$1.53M	Buy	126,647 +22,157	+21%	+$284K	﹤0.01%	3395
2024 Q3	$1.31M	Buy	104,490 +8,412	+9%	+$108K	﹤0.01%	3433
2024 Q2	$1.15M	Buy	96,078 +55,540	+137%	+$762K	﹤0.01%	3454
2024 Q1	$709K	Buy	40,538 +26,200	+183%	+$472K	﹤0.01%	3559
2023 Q4	$368K	Buy	14,338 +9,498	+196%	+$135K	﹤0.01%	3717
2023 Q3	$35K	Hold	4,840	–	–	﹤0.01%	4358
2023 Q2	$25.5K	Hold	4,840	–	–	﹤0.01%	4558
2023 Q1	$15K	Sell	4,840 -4,840	-50%	-$18.4K	﹤0.01%	4711
2022 Q4	$38.3K	Hold	9,680	–	–	﹤0.01%	4618
2022 Q3	$37K	Hold	9,680	–	–	﹤0.01%	4719
2022 Q2	$129K	Hold	9,680	–	–	﹤0.01%	4402
2022 Q1	$48K	Hold	9,680	–	–	﹤0.01%	4801
2021 Q4	$66K	Hold	9,680	–	–	﹤0.01%	4654
2021 Q3	$298K	Buy	9,680 +3,893	+67%	+$128K	﹤0.01%	4202
2021 Q2	$188K	Sell	5,787 -44,644	-89%	-$1.53M	﹤0.01%	4228
2021 Q1	$1.91M	Buy	50,431 +6,373	+14%	+$291K	﹤0.01%	3457
2020 Q4	$2.08M	Buy	44,058 +12,807	+41%	+$555K	﹤0.01%	3357
2020 Q3	$1.01M	Buy	31,251 +3,880	+14%	+$152K	﹤0.01%	3434
2020 Q2	$1.21M	Buy	+27,371	New	+$1.29M	﹤0.01%	3368
2019 Q2	–	Sell	-26,008	Closed	-$1.58M	–	3832
2019 Q1	$1.58M	Sell	26,008 -741	-3%	-$47.6K	﹤0.01%	3232
2018 Q4	$1.58M	Buy	26,749 +880	+3%	+$64.9K	﹤0.01%	3206
2018 Q3	$2.09M	Buy	25,869 +1,892	+8%	+$150K	﹤0.01%	3229
2018 Q2	$2.1M	Buy	23,977 +22,835	+2,000%	+$4.01M	﹤0.01%	3238
2018 Q1	$221K	Buy	+1,142	New	+$213K	﹤0.01%	3547
2015 Q3	–	Sell	-23	Closed	-$51K	–	3728
2015 Q2	$51K	Sell	23 -6	-21%	-$12K	﹤0.01%	3592
2015 Q1	$69K	Hold	29	–	–	﹤0.01%	3562
2014 Q4	$60K	Sell	29 -3	-9%	-$5.78K	﹤0.01%	3571
2014 Q3	$63K	Hold	32	–	–	﹤0.01%	3554
2014 Q2	$114K	Sell	32 -554	-95%	-$1.81M	﹤0.01%	3460
2014 Q1	$2.19M	Buy	586 +2	+0.3%	+$7.4K	﹤0.01%	3026
2013 Q4	$1.91M	Buy	584 +4	+0.7%	+$15.8K	﹤0.01%	3090
2013 Q3	$2.43M	Buy	580 +4	+0.7%	+$16.1K	﹤0.01%	2939
2013 Q2	$1.94M	Buy	+576	New	+$2.19M	﹤0.01%	3000

Other funds holding GYRE

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street's GYRE Position: Q1 2026 in Review

State Street increased its Gyre Therapeutics (GYRE) stake by 7% in Q1 2026, buying an estimated $110K and bringing the position to 216,326 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

State Street first reported a position in GYRE in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.43M in Q3 2013. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

State Street held 216,326 shares of Gyre Therapeutics worth $1.51M as of Q1 2026.
State Street bought 14,101 Gyre Therapeutics shares in Q1 2026, an estimated $110K.
Gyre Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3383 holding.
State Street first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 38 quarters since.
State Street's Gyre Therapeutics position peaked at $2.43M in Q3 2013.
56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.